SiRNA-mediated silencing of PD-1 ligands enhances tumor-specific human T-cell effector functions

Gene Therapy

Volumn 19, Issue 10, 2012, Pages 959-966

  Iwamura, K ^a   Kato, T ^a   Miyahara, Y ^a   Naota, H ^a   Mineno, J ^b   Ikeda, H ^a   Shiku, H ^a  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TAKARA BIO INC   (Japan)

Author keywords

Adoptive T cell therapy; PD 1; PD L1; PD L2; TCRa

Indexed keywords

GAMMA INTERFERON; MELANOMA ANTIGEN 4; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; RETROVIRUS VECTOR; SMALL INTERFERING RNA; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN;

ARTICLE; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CLONE; CELL THERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DNA MODIFICATION; EFFECTOR CELL; GENE SILENCING; GENETIC CODE; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; LYMPHOCYTE FUNCTION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; UPREGULATION;

ANTIGENS, CD274; ANTIGENS, NEOPLASM; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; GENETIC VECTORS; HUMANS; INTERFERON-GAMMA; NEOPLASM PROTEINS; PROGRAMMED CELL DEATH 1 LIGAND 2 PROTEIN; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSFECTION; UP-REGULATION;

EID: 84867396803     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2011.185     Document Type: Article

References (39)

1. June CH. Adoptive T cell therapy for cancer in the clinic. J Clin Invest 2007; 117: 1466-1476. (Pubitemid 46871329)
2. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006; 6: 715-727. (Pubitemid 44453458)
3. Gattinoni L, Powell Jr DJ, Rosenberg SA, Restifo NP. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol 2006; 6: 383-393.
4. Stephan MT, Ponomarev V, Brentjens RJ, Chang AH, Dobrenkov KV, Heller G et al. T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nat Med 2007; 13: 1440-1449. (Pubitemid 350224246)
5. Greenwald RJ, Latchman YE, Sharpe AH. Negative co-receptors on lymphocytes. Curr Opin Immunol 2002; 14: 391 -396. (Pubitemid 34327984)
6. Okazaki T, Iwai Y, Honjo T. New regulatory co-receptors: inducible co-stimulator and PD-1. Curr Opin Immunol 2002; 14: 779-782. (Pubitemid 35292426)
7. Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 2008; 8: 467-477. (Pubitemid 351733418)
8. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26: 677-704. (Pubitemid 351600389)
9. Brown JA, Dorfman DM, Ma FR, Sullivan EL, Munoz O, Wood CR et al. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol 2003; 170: 1257-1266. (Pubitemid 36139491)
10. Dong H, Strome SE, Matteson EL, Moder KG, Flies DB, Zhu G et al. Costimulating aberrant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis. J Clin Invest 2003; 111: 363 - 370. (Pubitemid 36182213)
11. Bennett F, Luxenberg D, Ling V, Wang IM, Marquette K, Lowe D et al. Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses. J Immunol 2003; 170: 711-718. (Pubitemid 36070520)
12. Kuipers H, Muskens F, Willart M, Hijdra D, van Assema FB, Coyle AJ et al. Contribution of the PD-1 ligands/PD-1 signaling pathway to dendritic cell-mediated CD4+ T cell activation. Eur J Immunol 2006; 36: 2472-2482. (Pubitemid 44420603)
13. Kim YS, Park GB, Lee HK, Song H, Choi IH, Lee WJ et al. Cross-linking of B7-H1 on EBV-transformed B cells induces apoptosis through reactive oxygen species production, JNK signaling activation, and fasL expression. J Immunol 2008; 181: 6158-6169.
14. Dembic Z, Haas W,Weiss S, McCubreyJ, Kiefer H,von Boehmer H etal. Transfer of specificity by murine alpha and beta T-cell receptor genes. Nature 1986; 320: 232-238. (Pubitemid 16040238)
15. Schmitt TM, Ragnarsson GB, Greenberg PD. T cell receptor gene therapy for cancer. Hum Gene Ther 2009; 20: 1240-1248.
16. Larin SS, Georgiev GP, Kiselev SL. Gene transfer approaches in cancer immunotherapy. Gene Therapy 2004; 11(Suppl 1): S18-S25. (Pubitemid 39359443)
17. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008; 8: 299-308. (Pubitemid 351430867)
18. Miyahara Y, Naota H, Wang L, Hiasa A, Goto M, Watanabe M et al. Determination of cellularly processed HLA-A2402-restricted novel CTL epitopes derived from two cancer germ line genes, MAGE-A4 and SAGE. Clin Cancer Res 2005; 11: 5581-5589. (Pubitemid 41060836)
19. Hiasa A, Hirayama M, Nishikawa H, Kitano S, Nukaya I, Yu SS et al. Long-term phenotypic, functional and genetic stability of cancer-specific T-cell receptor (TCR) alphabeta genes transduced to CD8+ T cells. Gene Therapy 2008; 15: 695-699. (Pubitemid 351524524)
20. Okamoto S, Mineno J, Ikeda H, Fujiwara H, Yasukawa M, Shiku H et al. Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by specific silencing of endogenous TCR. Cancer Res 2009; 69: 9003-9011.
21. Roy M, Aruffo A, Ledbetter J, Linsley P, Kehry M, Noelle R. Studies on the interdependence ofgp39 and B7 expression and function during antigen-specific immune responses. Eur J Immunol 1995; 25: 596-603.
22. Kato T, Hakamada R, Yamane H, Nariuchi H. Induction of IL-12 p40 messenger RNA expression and IL-12 production of macrophages via CD40-CD40 ligand interaction. J Immunol 1996; 156: 3932 - 3938. (Pubitemid 26139944)
23. Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 2007; 27: 111-122. (Pubitemid 47089023)
24. Mirza N, Duque MA, Dominguez AL, Schrum AG, Dong H, Lustgarten J. B7-H1 expression on old CD8+ T cells negatively regulates the activation of immune responses in aged animals. J Immunol 2010; 184: 5466 - 5474.
25. Messal N, Serriari NE, Pastor S, Nunes JA, Olive D. PD-L2 is expressed on activated human T cells and regulates their function. Mol Immunol 2011; 48: 2214-2219.
26. Nourry C, Grant SG, Borg JP. PDZ domain proteins: plug and play! Sci STKE 2003; 2003: RE7.
27. Borkner L, Kaiser A, van de Kasteele W, Andreesen R, Mackensen A, Haanen JB et al. RNA interference targeting programmed death receptor-1 improves immune functions of tumor-specific T cells. Cancer Immunol Immunother 2010; 59: 1173-1183.
28. Greenwald RJ, Freeman GJ, Sharpe AH.The B7 family revisited. Annu RevImmunol 2005; 23: 515-548. (Pubitemid 40563179)
29. Liu Y, Yu Y, Yang S, Zeng B, Zhang Z, Jiao G et al. Regulation ofarginase I activity and expression by both PD-1 and CTLA-4 on the myeloid-derived suppressor cells. Cancer Immunol Immunother 2009; 58: 687-697.
30. Poschke I, Mougiakakos D, Hansson J, Masucci GV, Kiessling R. Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res 2010; 70: 4335-4345.
31. Liu X, GaoJX,Wen J,Yin L, Li O, ZuoTetal. B7DC/PDL2 promotes tumor immunity by a PD-1-independent mechanism. J Exp Med 2003; 197: 1721 -1730. (Pubitemid 36745347)
32. Wang S, Bajorath J, Flies DB, Dong H, Honjo T, Chen L. Molecular modeling and functional mapping of B7-H1 and B7-DC uncouple costimulatory function from PD-1 interaction.JExpMed2003; 197: 1083-1091. (Pubitemid 36570064)
33. Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009; 114: 535-546.
34. Finn OJ. Cancer immunology. N Engl J Med 2008; 358: 2704-2715.
35. Blank C, Mackensen A. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother 2007; 56: 739-745. (Pubitemid 46348742)
36. Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 2009; 182: 4499-4506.
37. Bendle GM, Linnemann C, Hooijkaas AI, Bies L, de Witte MA, Jorritsma A et al. Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nat Med 2010; 16: 565-570.
38. Naota H, Miyahara Y, Okumura S, Kuzushima K, Akatsuka Y, Hiasa A et al. Generation of peptide-specific CD8+ T cells by phytohemagglutinin-stimulated antigen-mRNA-transduced CD4+ T cells. J Immunol Methods 2006; 314: 54-66. (Pubitemid 44189426)
39. Nishikawa H, Tanida K, Ikeda H, Sakakura M, Miyahara Y, Aota T et al. Role of SEREX-defined immunogenic wild-type cellular molecules in the development of tumor-specific immunity. Proc Natl Acad Sci USA 2001; 98: 14571 -14576. (Pubitemid 33121433)